Related Experiment Video
Updated: May 10, 2026
05:41
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Challenges and opportunities for faecal microbiota transplantation therapy
1Molecular Microbiology Research Laboratory, Institute of Pharmaceutical Science, King's College London, London, UK.
Epidemiology and Infection
|June 6, 2013
Summary
Fecal microbiota transplantation (FMT) offers a promising non-antibiotic approach to combat rising Clostridium difficile infections. However, careful consideration of potential infective agent transmission is crucial for safe and effective therapy.
Area of Science:
- Microbiology
- Gastroenterology
- Infectious Diseases
Background:
- Clostridium difficile infections are increasing, driven by hypervirulent and antibiotic-resistant strains, necessitating urgent non-antibiotic treatments.
- Fecal microbiota transplantation (FMT) leverages healthy gut bacteria to displace pathogens and address gut dysbiosis.
- Advances in technology enhance understanding of FMT's mechanisms, duration, and extent of beneficial bacterial community changes.
Purpose of the Study:
- To explore the potential of fecal microbiota transplantation (FMT) as an alternative treatment for Clostridium difficile infections.
- To highlight the need for non-antibiotic strategies due to increasing infection rates and resistance.
- To examine the role of technological advancements in understanding FMT.
Main Methods:
- Review of current research on Clostridium difficile infection epidemiology and treatment challenges.
- Analysis of the principles and evidence supporting fecal microbiota transplantation (FMT).
- Discussion of recent technological advancements in characterizing microbial community dynamics.
Main Results:
- Fecal microbiota transplantation (FMT) shows potential in treating conditions associated with gut dysbiosis.
- Understanding of beneficial bacterial shifts and their duration has improved with new technologies.
- The efficacy of FMT is a primary research focus, but potential risks require attention.
Conclusions:
- Fecal microbiota transplantation (FMT) presents a viable alternative to antibiotics for Clostridium difficile infections.
- Further research is needed to optimize FMT protocols and ensure patient safety.
- Careful consideration of infectious agent transmission risks is essential for the clinical application of FMT.
Related Concept Videos
01:22Introduction to the Human Microbiota
Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity, and disease...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:18Functions of the Gut Microbiota
The gut microbiota includes trillions of microorganisms that colonize the human gastrointestinal tract, including bacteria, archaea, viruses, and fungi. This complex ecosystem plays a critical role in maintaining intestinal and systemic health. Most of these microbes inhabit the large intestine, establishing a relatively stable and diverse community that contributes to gut homeostasis through various metabolic, immunological, and protective mechanisms.Dominant bacterial phyla, such as...
01:30Development of Human Microbiota
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
01:50What is Monogastric Digestion?
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
01:27Microbiota of the Large Intestine
The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...